[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
From the JAMA Network
June 23/30, 2015

Metformin as Initial Oral Therapy in Type 2 Diabetes

Author Affiliations
  • 1San Francisco General Hospital Primary Care Residency, Department of Internal Medicine, University of California, San Francisco
  • 2Department of Medicine, University of California, San Francisco
  • 3Division of Endocrinology, San Francisco General Hospital, San Francisco, California
JAMA. 2015;313(24):2484-2485. doi:10.1001/jama.2015.2765

Eleven drug classes are available as initial monotherapy for type 2 diabetes, presenting a vast choice in terms of therapeutic mechanism, adverse effect profile, efficacy, and cost. In 2012 in the United States, 18 million people filled 121 million prescriptions for these agents, and prescribing rates have increased rapidly—nearly 50% in 9 years.1 Given the prevalence of type 2 diabetes, identifying the optimal initial oral therapy is of national health policy importance.

First Page Preview View Large
First page PDF preview
First page PDF preview